For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
In the latest session, CytomX Therapeutics Inc (NASDAQ: CTMX) closed at $4.0 up 4.99% from its previous closing price of $3.81. In other words, the price has increased by $4.99 from its previous closing price. On the day, 2.19 million shares were traded. CTMX stock price reached its highest trading level at $4.015 during the session, while it also had its lowest trading level at $3.655.
Ratios:
For a deeper understanding of CytomX Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.64 and its Current Ratio is at 3.64. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Cantor Fitzgerald on September 22, 2025, initiated with a Overweight rating and assigned the stock a target price of $6.
On July 31, 2025, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $7.Oppenheimer initiated its Outperform rating on July 31, 2025, with a $7 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 06 ’25 when McCarthy Sean A. sold 101,793 shares for $4.54 per share. The transaction valued at 461,906 led to the insider holds 987,891 shares of the business.
Sean McCarthy bought 101,793 shares of CTMX for $461,909 on Nov 06 ’25. On Jun 16 ’25, another insider, Ogden Christopher, who serves as the Chief Financial Officer of the company, sold 10,614 shares for $2.69 each. As a result, the insider received 28,540 and left with 226,271 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTMX now has a Market Capitalization of 677741568 and an Enterprise Value of 539711552. As of this moment, CytomX’s Price-to-Earnings (P/E) ratio for their current fiscal year is 9.56. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.96 while its Price-to-Book (P/B) ratio in mrq is 6.15. Its current Enterprise Value per Revenue stands at 4.75 whereas that against EBITDA is 22.006.
Stock Price History:
The Beta on a monthly basis for CTMX is 2.43, which has changed by 2.2844827 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, CTMX has reached a high of $4.62, while it has fallen to a 52-week low of $0.40. The 50-Day Moving Average of the stock is 11.32%, while the 200-Day Moving Average is calculated to be 86.77%.
Shares Statistics:
For the past three months, CTMX has traded an average of 3.62M shares per day and 2116150 over the past ten days. A total of 165.07M shares are outstanding, with a floating share count of 127.86M. Insiders hold about 24.54% of the company’s shares, while institutions hold 65.29% stake in the company. Shares short for CTMX as of 1763078400 were 29319732 with a Short Ratio of 8.10, compared to 1760486400 on 28399194. Therefore, it implies a Short% of Shares Outstanding of 29319732 and a Short% of Float of 17.930001.
